MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41419-026-08434-5

Медицинская библиотека · Cell death & disease · 2026

BCL-xL as a therapeutic target in cetuximab-refractory colorectal cancer.

Asmanidou Stella, Thiel Julia, Ekstrom Thomas L, Schueler Julia, Oswald Eva, Metzger Patrick, Blaumeiser Andreas C, Boerries Melanie, Wiebl Lisa-Marie, Schiffler Ronja, Tamas Raluca, Essmann Frank, Dong Meng, Johnsen Steven A, Kontermann Roland E, Olayioye Monilola A

СтатьяПеревод пока не подготовлен

Аннотация

Despite recent medical advances, colorectal cancer (CRC) remains the second-leading cause of cancer-related death worldwide. For patients with KRAS wild-type metastatic CRC, the monoclonal antibody cetuximab, which targets the epidermal growth factor receptor (EGFR), is an approved treatment option. However, therapeutic success is often limited by the emergence of drug-resistant cancer cell populations within a few months. Therefore, alternative strategies to effectively target cetuximab-refractory CRC are urgently needed. Here, we sought to identify second-line therapeutic strategies using a CRC cell line with acquired cetuximab resistance as a model. Transcriptomic profiling of the resistant cells identified the apoptosis pathway as a potential therapeutic target, which was supported by their increased susceptibility to BH3-mimetics targeting the anti-apoptotic proteins MCL-1 and BCL-xL under both 2D and 3D culture conditions. These findings were validated in organotypic CRC slice cultures generated from cetuximab-resistant patient-derived xenografts (PDXs). Multiplex immunofluorescence staining demonstrated that BCL-xL inhibition effectively triggered apoptosis in heterogeneous PDX tumor slice models, including models harboring oncogenic BRAF mutations. Our findings suggest that cetuximab-resistant CRC retains apoptotic competence, and that BCL-xL inhibition serves as a robust alternative therapeutic strategy that is largely independent of the tumor mutational profile.

Для цитирования: Asmanidou Stella, Thiel Julia, Ekstrom Thomas L, Schueler Julia, Oswald Eva, Metzger Patrick, Blaumeiser Andreas C, Boerries Melanie, Wiebl Lisa-Marie, Schiffler Ronja, Tamas Raluca, Essmann Frank, Dong Meng, Johnsen Steven A, Kontermann Roland E, Olayioye Monilola A. BCL-xL as a therapeutic target in cetuximab-refractory colorectal cancer.. Cell death & disease. 2026. DOI: 10.1038/s41419-026-08434-5.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.